Coya Therapeutics (COYA) Accumulated Expenses (2021 - 2026)

Coya Therapeutics (COYA) has 6 years of Accumulated Expenses data on file, last reported at $352347.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 12.11% year-over-year to $352347.0; the trailing twelve-month figure through Mar 2026 stood at $352347.0 (up 12.11% YoY), and the FY2025 full-year result was $3.6 million, up 160.29% from the prior year.
• Accumulated Expenses retreated to $352347.0 in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.6 million in Q4 2025 to a low of $314273.0 in Q1 2025.
• A 5-year average of $1.2 million and a median of $974546.5 in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 590.6% in 2022 and plunged 84.61% in 2025, its largest moves.
• Tracing COYA's Accumulated Expenses over 5 years: stood at $2.0 million in 2022, then plunged by 46.16% to $1.1 million in 2023, then grew by 28.37% to $1.4 million in 2024, then soared by 160.29% to $3.6 million in 2025, then plunged by 90.25% to $352347.0 in 2026.
• Business Quant data shows COYA's Accumulated Expenses at $352347.0 in Q1 2026, $3.6 million in Q4 2025, and $945840.0 in Q3 2025.